Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H22N2O2 |
Molecular Weight | 322.4009 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H]3OC[C@@H]1[C@@]4([H])N(C)C[C@]2(C=C)[C@@]4([H])[C@@]35C(=O)NC6=CC=CC=C56
InChI
InChIKey=NFYYATWFXNPTRM-QJICHLCESA-N
InChI=1S/C20H22N2O2/c1-3-19-10-22(2)16-11-9-24-15(8-13(11)19)20(17(16)19)12-6-4-5-7-14(12)21-18(20)23/h3-7,11,13,15-17H,1,8-10H2,2H3,(H,21,23)/t11-,13+,15+,16+,17-,19-,20-/m0/s1
Gelsemine is the principal alkaloid in Gelsemium sempervirens Ait. A single intrathecal injection of gelsemine produced potent and specific antinociception in formalin-induced tonic pain, bone cancer-induced mechanical allodynia, and spinal nerve ligation-induced painful neuropathy. Gelsemine exhibits potent and specific antinociception in chronic pain by acting at spinal α3 glycine receptors. Gelsemine is an effective agent for treatment of both neuropathic pain and sleep disturbance in PSNL mice; anterior cingulate cortex might play a role in the hypnotic effects of gelsemine.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26388157 | https://www.ncbi.nlm.nih.gov/pubmed/23850351
Curator's Comment: CNS active in animal models.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4093780
Curator's Comment: Gelsemine, was first isolated by Wormley in 1870.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P24524 Gene ID: NA Gene Symbol: Glra3 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23886522 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Indole synthesis by radical cyclization of o-alkenylphenyl isocyanides and its application to the total synthesis of natural products. | 2002 |
|
Explorations in organic chemistry leading to the total synthesis of (+/-)-gelsemine. | 2002 Aug 21 |
|
Gelsemine: a thought-provoking target for total synthesis. | 2003 Jan 3 |
|
A convenient one-pot procedure to afford bicyclic molecules by stereospecific iron carbonyl mediated [6 + 2] ene-type cyclization: a possible approach to gelsemine. | 2003 Nov 5 |
|
Use of the intramolecular Heck reaction for forming congested quaternary carbon stereocenters. Stereocontrolled total synthesis of (+/-)-gelsemine. | 2005 Dec 28 |
|
Aza-cope rearrangement-mannich cyclizations for the formation of complex tricyclic amines: stereocontrolled total synthesis of (+/-)-gelsemine. | 2005 Dec 28 |
|
Double conjugate addition of a nitropropionate ester to a quinone monoketal: synthesis of an advanced intermediate to (+/-)-gelsemine. | 2007 Aug 2 |
|
Pattern recognition in retrosynthetic analysis: snapshots in total synthesis. | 2007 Jun 8 |
|
Regulation of neurosteroid allopregnanolone biosynthesis in the rat spinal cord by glycine and the alkaloidal analogs strychnine and gelsemine. | 2008 Apr 22 |
|
Nectar secondary compounds affect self-pollen transfer: implications for female and male reproduction. | 2008 Aug |
|
Steroids, alkaloids, and coumarins from Gelsemium sempervirens. | 2008 Dec |
|
A concise approach to a gelsemine core structure using an oxygen to carbon bridge swapping strategy. | 2008 Nov 6 |
|
Confirmation of gelsemium poisoning by targeted analysis of toxic gelsemium alkaloids in urine. | 2009 Jan-Feb |
|
Assays of homeopathic remedies in rodent behavioural and psychopathological models. | 2009 Oct |
|
Consumption of a nectar alkaloid reduces pathogen load in bumble bees. | 2010 Jan |
|
The genus Gelsemium: An update. | 2010 Jul |
|
Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice. | 2010 Jul |
|
Simultaneous determination of six alkaloids in blood and urine using a hydrophilic interaction liquid chromatography method coupled with electrospray ionization tandem mass spectrometry. | 2010 Oct |
|
Antitumor activity of two gelsemine metabolites in rat liver microsomes. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26388157
Curator's Comment: Oral route - Rabbits: were randomly divided into five groups and fed normal diet, hypercholesterolemic diet (1% cholesterol), or hypercholesterolemic diet (1% cholesterol) supplemented with gelsemine (1, 5, or 25 mg/kg). https://www.ncbi.nlm.nih.gov/pubmed/25213292
In PSNL mice, gelsemine (2 and 4 mg/kg) increased the mechanical threshold for 4 h and prolonged the thermal latencies for 3 h. Furthermore, gelsemine (4 mg/kg, administered at 6:30 AM) increased non-rapid eye movement (non-REM, NREM) sleep, decreased wakefulness, but did not affect REM sleep during the first 3 h in PSNL mice.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23886522
Differential concentrations of gelsemine (1, 3, 10,
30, 100, 300, and 1000 uM) or glycine (3, 10, 30, 100, 300, and
1000 uM) were added to H3
-strychnine and the rat crude membrane.
Both gelsemine and glycine concentration-dependently
displaced H3
-strychnine binding by a maximum displacement
of 100%. The IC50 values of gelsemine and glycine were
43.8 and 82.1 uM, and their Ki values were 21.9 and 41.0 uM,
respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
208-095-2
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | |||
|
Gelsemine
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | |||
|
5Y13A78Z72
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | |||
|
m5688
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
21729
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | |||
|
509-15-9
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | |||
|
5390854
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | |||
|
3488
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY | |||
|
DTXSID40878487
Created by
admin on Sat Dec 16 07:57:46 GMT 2023 , Edited by admin on Sat Dec 16 07:57:46 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD